Full bibliography
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic
Resource type
Report
Authors/contributors
- Halucenex Life Sciences Inc. (Author)
- Everest Clinical Research (Contributor)
- KGK Science Inc. (Contributor)
Title
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic
Abstract
Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance symptoms, along with comorbidities such as anxiety, depression, and increased risk for self-medicating substance abuse. Currently, there are only two approved medications in the United States (US) for PTSD, paroxetine and sertraline.
Psychedelic medications, including psilocybin, have recently received breakthrough designation by the US Food and Drug Administration (FDA) for other psychiatric indications. Although no formal clinical trials have yet investigated psychedelic substances for the treatment of PTSD, the available evidence warrants such an investigation. The present study aims to investigate the effect of psilocybin on treatment-resistant PTSD.
Report Number
NCT05243329
Report Type
Clinical trial registration
Institution
Date
October 3, 2022
Short Title
Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Accessed
2022-11-24
Library Catalog
Extra
submitted: December 15, 2021
Citation
Halucenex Life Sciences Inc. (2022). Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic (Clinical Trial Registration No. NCT05243329). clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT05243329
Link to this record